急性白血病患者卵巢组织冷冻保存与移植的安全性:病例系列
该病例系列分析4例急性髓系白血病和2例急性淋巴细胞白血病女性卵巢组织冷冻保存与移植的临床、组织病理学和分子数据,所有患者移植前筛查白血病浸润均为阴性,移植后卵巢功能均恢复,中位随访51个月无复发,2例各有1次活产。
要点
- 6例急性白血病患者卵巢组织移植前筛查均未检出白血病细胞。
- 移植后所有患者卵巢功能恢复,中位时间3.0个月(范围2.5-4.0)。
- 中位随访51个月(四分位距20-74)所有患者无复发,2例各有1次活产。
核心结论
- 长期随访显示,接受异基因造血干细胞移植的急性白血病患者卵巢组织移植后无疾病复发证据。
- 作者提出,对于因异基因造血干细胞移植前预处理化疗而面临性腺毒性的年轻白血病女性,不应将卵巢组织冷冻保存排除在生育力保存选项之外。
研究设计与样本
- 病例系列,纳入4例急性髓系白血病和2例急性淋巴细胞白血病女性,分析其卵巢组织冷冻保存与移植的临床、组织病理学和分子数据。
- 卵巢皮质以慢速冷冻法冷冻保存66%至100%,所有患者均接受含大剂量多药烷化剂预处理化疗以进行异基因造血干细胞移植。
主要发现
- 卵巢组织冷冻保存时中位年龄20岁(四分位距15-32),冷冻保存前平均血清抗苗勒管激素为1.9±1.7 ng/mL。
- 所有病例卵巢组织筛查白血病细胞均为阴性。
- 卵巢组织冷冻保存后中位74.5个月(四分位距41-120)行腹腔镜(伴或不伴机器人辅助)卵巢移植。
- 移植后所有患者卵巢功能恢复,中位时间3.0个月(范围2.5-4.0),2例女性各有1次活产。
- 移植后中位移植物存活时间35.5个月(四分位距18-57);中位随访51个月(四分位距20-74)所有患者无复发。
关键数值与推荐
- 卵巢组织移植前评估窦卵泡计数、血清抗苗勒管激素和促卵泡激素水平以确认原发性卵巢功能不全。
- 所有受体均经血液肿瘤科医生确认许可。
- 代表性皮质条带通过组织学(苏木精-伊红染色)、免疫组化(CD3、CD20、CD34、CD68、CD117、CD163、PAX-5、Tdt、溶菌酶和MPO)及适当情况下的分子标志物评估(BCR/ABL p190和AML1/ETO)筛查白血病浸润。
临床怎么用
- 作者提出,对于因异基因造血干细胞移植前预处理化疗而面临性腺毒性的年轻白血病女性,不应将卵巢组织冷冻保存排除在生育力保存选项之外。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With increased success, ovarian tissue cryopreservation has recently become a standard technique for fertility preservation. However, malignant cell introduction through ovarian tissue transplantation remains a major concern for patients with acute leukemias. OBJECTIVE: This study aimed to investigate the safety of performing autologous ovarian tissue transplantation in survivors of acute leukemia. STUDY DESIGN: Clinical, histopathological, and molecular data of 4 women with acute myeloid leukemia and 2 women with acute lymphoblastic leukemia who underwent ovarian tissue cryopreservation and transplantation were analyzed in this case series. Following cryopreservation of 66% to 100% of an ovarian cortex with a slow freezing method, all women received high-dose multiagent alkylating preconditioning chemotherapy for allogeneic hematopoietic stem cell transplantation. Before the ovarian tissue transplantation, (1) antral follicle counts, serum antimüllerian hormone and follicle-stimulating hormone levels were assessed to confirm primary ovarian insufficiency; (2) all recipients were cleared by their hematologist-oncologists; (3) representative cortical strips were screened for leukemia infiltration by histologic (hematoxylin and eosin staining), immunohistochemical (CD3, CD20, CD34, CD68, CD117, CD163, PAX-5, Tdt, lysozyme, and MPO), and molecular marker evaluation (BCR/ABL p190 and AML1/ETO) where appropriate. RESULTS: The median age was 20 years (interquartile range, 15-32) at ovarian tissue cryopreservation. Before undergoing hematopoietic stem cell transplantation, all patients received induction or consolidation chemotherapy that included cytarabine + daunorubicin or Berlin-Frankfurt-Munich-95 protocol and were in remission. The mean serum antimüllerian hormone was 1.9±1.7 ng/mL before ovarian tissue cryopreservation. In all cases, ovarian tissue screening for leukemic cells was negative. Ovarian transplantation was performed laparoscopically with or without robotic assistance, after a median of 74.5 months (interquartile range, 41-120) after ovarian tissue cryopreservation. Ovarian function resumed in all patients after a median of 3.0 months (range, 2.5-4.0), and 2 women had 1 live birth each. The median graft longevity was 35.5 months (interquartile range, 18-57) after ovarian tissue transplantation. After a median follow-up of 51 months (interquartile range, 20-74), all patients remained relapse-free. In 1 patient, the graft was removed during cesarean delivery and was negative for immunochemical leukemia markers. CONCLUSION: Our long-term follow-up demonstrated no evidence of disease relapse after ovarian tissue transplantation in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation. This safety profile may be explained by the fact that these patients are induced into remission by nongonadotoxic induction chemotherapy before undergoing ovarian tissue cryopreservation. We propose that ovarian tissue cryopreservation should not be excluded as a fertility preservation option for young women with leukemia who are due to receive preconditioning chemotherapy before allogeneic hematopoietic stem cell transplantation.
引用
- Sönmezer M, Şükür YE, Saçıntı KG, et al. Safety of ovarian cryopreservation and transplantation in patients with acute leukemia: a case series. Am J Obstet Gynecol. 2023. PMID: 37666382. doi:10.1016/j.ajog.2023.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。